{
    "organizations": [],
    "uuid": "c2b05ee60bab3e4d558042d48bf7dab436d13ddd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mauna-kea-cellvizio-demonstrates-s/brief-mauna-kea-cellvizio-demonstrates-superior-identification-of-patients-at-risk-for-esophageal-cancer-idUSFWN1RP172",
    "ord_in_thread": 0,
    "title": "BRIEF-Mauna Kea Cellvizio Demonstrates Superior Identification Of Patients At Risk For Esophageal Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 13 (Reuters) - MAUNA KEA TECHNOLOGIES SAS:\n* MAUNA KEA TECHNOLOGIES’ CELLVIZIO® DEMONSTRATES SUPERIOR IDENTIFICATION OF PATIENTS AT RISK FOR ESOPHAGEAL CANCER COMPARED TO CURRENT DIAGNOSTIC STANDARD\n* RESULTS FROM NEW CLINICAL STUDY THAT ENROLLED 172 PATIENTS AT 8 NON-ACADEMIC CENTERS IN UNITED-STATES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-13T14:11:00.000+03:00",
    "crawled": "2018-04-14T13:40:18.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "mauna",
        "kea",
        "technology",
        "sa",
        "mauna",
        "kea",
        "technology",
        "demonstrates",
        "superior",
        "identification",
        "patient",
        "risk",
        "esophageal",
        "cancer",
        "compared",
        "current",
        "diagnostic",
        "standard",
        "result",
        "new",
        "clinical",
        "study",
        "enrolled",
        "patient",
        "center",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}